{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:38:13Z","timestamp":1793036293380,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.annonc.2021.12.002","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T01:57:23Z","timestamp":1639619843000},"page":"288-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":280,"title":["The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"S.","family":"Horwitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.A.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Tr\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.L.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Menne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Belada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Ill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-P.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"H\u00fcttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Puhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2021.12.002_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib2","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/bjh.14477","article-title":"The survival outcome of patients with relapsed\/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma","volume":"176","author":"Chihara","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2021.12.002_bib4","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.annonc.2021.12.002_bib6","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1200\/JCO.2017.73.8195","article-title":"International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma","volume":"35","author":"Maurer","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib7","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2021.12.002_bib9","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/annonc\/mdq635","article-title":"Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"22","author":"Kluin-Nelemans","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","article-title":"A\u00a0multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study","volume":"54","author":"Foss","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2021.12.002_bib11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2147\/OTT.S189825","article-title":"Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis","volume":"12","author":"Deng","year":"2019","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.annonc.2021.12.002_bib12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2021.12.002_bib13","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.annonc.2021.12.002_bib14","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib15","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.12.002_bib16","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.25513","article-title":"Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification and management","volume":"94","author":"Zain","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annonc.2021.12.002_bib17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib19","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib20","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.annonc.2021.12.002_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib22","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1200\/JCO.2019.37.15_suppl.7543","article-title":"Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib23","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1158\/1538-7445.AM2015-2469","article-title":"Brentuximab vedotin-mediated immunogenic cell death","volume":"75","author":"Gardai","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2021.12.002_bib24","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2021.12.002_bib25","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Muller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annonc.2021.12.002_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hon.149_2631","article-title":"Response to brentuximab vedotin by CD30 expression: results from five trials in PTCL, CTCL, and B-cell lymphomas","volume":"37","author":"Jagadeesh","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib27","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2021.12.002_bib29","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous t-cell lymphoma and lymphomatoid papulosis","volume":"33","author":"Duvic","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib30","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1080\/10428194.2016.1256481","article-title":"Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry","volume":"58","author":"Bartlett","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2021.12.002_bib31","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib32","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood-2007-06-097014","article-title":"Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30","volume":"110","author":"Oflazoglu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib33","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-136402","article-title":"Trial-in-progress: frontline brentuximab vedotin and CHP (A+CHP) in patients with peripheral T-cell lymphoma with less than 10% CD30 expression","volume":"136","author":"Jagadeesh","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.annonc.2021.12.002_bib35","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/blood-2019-121523","article-title":"A\u00a0phase 2 study of retreatment with brentuximab vedotin in patients with cHL, sALCL or other CD30-expressing PTCL","volume":"134","author":"Ahmed","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib36","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2019-123166","article-title":"Preliminary results from a phase 2 trial of brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-positive peripheral T-cell lymphomas","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2021.12.002_bib37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2021-151105","article-title":"Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone (CHEP-BV) followed by BV consolidation in patients with CD30-expressing peripheral T-cell lymphomas","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421048754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421048754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:07:41Z","timestamp":1760335661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421048754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0923753421048754"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}